低剂量白细胞介素-2诱导调节性T细胞及对系统性硬化症的疗效:干预性开放标签1期-2a期研究
第8天主要终点达标,调节性T细胞频率较基线增加1.8±0.5倍(p=0.0015),治疗耐受良好且无相关严重不良事件,6个月时改良Rodnan皮肤评分、疾病活动度及肺功能等指标保持稳定。
要点
- 治疗耐受良好,未发生与治疗相关的严重不良事件。
- 6个月时改良Rodnan皮肤评分、疾病活动度及肺功能等临床指标保持稳定。
核心结论
- 研究期间临床体征保持稳定。
- 作者认为这为开展充分把握度的2期疗效试验研究低剂量白细胞介素-2在系统性硬化症中的治疗疗效打开了大门。
研究设计与样本
- TRANSREG开放标签2a期篮式试验的一部分,在多种自身免疫病中开展。
- 研究纳入9例无严重器官受累的系统性硬化症患者。
- 在基线至第6个月之间进行实验室和临床评估。
主要发现
- 第8天主要终点(调节性T细胞频率)达标,调节性T细胞在CD4+ T淋巴细胞中的比例较基线增加1.8±0.5倍(p=0.0015)。
- 效应T细胞和B细胞均无显著变化。
- 低剂量白细胞介素-2耐受良好,未发生与治疗相关的严重不良事件。
- 第6个月时改良Rodnan皮肤评分和Valentini评分总体保持稳定。
- 研究期间疾病活动度和严重度指标、EuroQL-5D-5L评估的生活质量及肺功能检查参数保持稳定。
关键数值与推荐
- 第8天调节性T细胞频率较基线增加1.8±0.5倍(p=0.0015)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic sclerosis (SSc) is a chronic autoimmune disease, with impaired immune response, increased fibrosis and endothelial dysfunction. Regulatory T cells (Tregs), which are essential to control inflammation, tissue repair and autoimmunity, have a decreased frequency and impaired function in SSc patients. Low-dose interleukin-2 (IL-2LD) can expand and activate Tregs and has, therefore, a therapeutic potential in SSc. OBJECTIVE: We aimed to assess the safety and biological efficacy of IL-2LD in patients with SSc. METHODS: As part of the TRANSREG open-label phase IIa basket trial in multiple autoimmune diseases, we studied nine patients with SSc without severe organ involvement. Patients received 1 million international units (MIU)/day of IL-2 for 5 days, followed by fortnightly injections for 6 months. Laboratory and clinical evaluations were performed between baseline and month 6. RESULTS: At day 8, the primary endpoint (Treg frequency) was reached with a 1.8±0.5-fold increase of Treg levels among CD4+ T lymphocytes (p=0.0015). There were no significant changes in effector T cells nor in B cells. IL-2LD was well tolerated, and no serious adverse events related to treatment occurred. There was a globally stable measurement in the modified Rodnan skin score and Valentini score at month 6. Disease activity and severity measures, the quality of life evaluated by EuroQL-5D-5L and pulmonary function test parameters remained stable during the study period. CONCLUSION: IL-2LD at a dosage of 1 MIU/day safely and selectively activates and expands Tregs. Clinical signs remain stable during the study period. This opens the door to properly powered phase II efficacy trials investigating IL-2LD therapeutic efficacy in SSc.
引用
- Barde F, Lorenzon R, Vicaut E, et al. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study. RMD Open. 2024. PMID: 38580347. doi:10.1136/rmdopen-2023-003500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。